Wockhardt has reported “substantial growth” of 66% to INR3.87bn ($52m) in its UK business for the firm’s financial second quarter ending 30 September 2021, helping the company’s overall revenue to grow by 21% to INR8.62bn. The company noted that its UK business contributed about 45% of its global revenues, with the majority of growth coming from its COVID-19 vaccine business.
Wockhardt’s UK Business Continues To Grow
As Company Records Double-Digit Growth In India Market
Wockhardt’s UK segment continues to grow as the company records a 66% increase for the second quarter ending 30 September 2021. The company’s India market and Irish market performed well, while its emerging markets and US market failed to deliver.
More from Deals
More from Business
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.